Cargando…
Therapy and Outcome of Prolonged Veno-Venous ECMO Therapy of Critically Ill ARDS Patients
Veno-venous Extracorporeal Membrane Oxygenation (VV-ECMO) therapy has become increasingly used and established in many hospitals as a routine treatment. With ECMO-therapy being a resource-demanding procedure, it is of interest whether a more prolonged VV-ECMO treatment would hold sufficient therapeu...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10094941/ https://www.ncbi.nlm.nih.gov/pubmed/37048583 http://dx.doi.org/10.3390/jcm12072499 |
_version_ | 1785023961953730560 |
---|---|
author | Flinspach, Armin N. Raimann, Florian J. Bauer, Frederike Zacharowski, Kai Ippolito, Angelo Booke, Hendrik |
author_facet | Flinspach, Armin N. Raimann, Florian J. Bauer, Frederike Zacharowski, Kai Ippolito, Angelo Booke, Hendrik |
author_sort | Flinspach, Armin N. |
collection | PubMed |
description | Veno-venous Extracorporeal Membrane Oxygenation (VV-ECMO) therapy has become increasingly used and established in many hospitals as a routine treatment. With ECMO-therapy being a resource-demanding procedure, it is of interest whether a more prolonged VV-ECMO treatment would hold sufficient therapeutic success. Our retrospective study included all VV-ECMO runs from 1 January 2020 to 31 June 2022. We divided all runs into four groups (<14 days, 14–27, 28–49, 50+) of different durations and looked for differences overall in hospital survival. Additionally, corresponding treatments and therapeutic modalities, as well as laboratory results, were analyzed. We included 117 patients. Of those, 97 (82.9%) received a VV-ECMO treatment longer than two weeks. We did not find a significant association between ECMO duration (p = 0.15) and increased mortality though a significant correlation between the patients’ age and their probability of survival (p = 0.02). Notably, we found significantly lower interleukin-6 levels with an increase in therapy duration (p < 0.01). Our findings show no association between the duration of ECMO therapy and mortality. Thus, the treatment duration alone may not be used for making assumptions about the prospect of survival. However, attention is also increasingly focused on long-term outcomes, such as post-intensive care syndrome with severe impairments. |
format | Online Article Text |
id | pubmed-10094941 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-100949412023-04-13 Therapy and Outcome of Prolonged Veno-Venous ECMO Therapy of Critically Ill ARDS Patients Flinspach, Armin N. Raimann, Florian J. Bauer, Frederike Zacharowski, Kai Ippolito, Angelo Booke, Hendrik J Clin Med Article Veno-venous Extracorporeal Membrane Oxygenation (VV-ECMO) therapy has become increasingly used and established in many hospitals as a routine treatment. With ECMO-therapy being a resource-demanding procedure, it is of interest whether a more prolonged VV-ECMO treatment would hold sufficient therapeutic success. Our retrospective study included all VV-ECMO runs from 1 January 2020 to 31 June 2022. We divided all runs into four groups (<14 days, 14–27, 28–49, 50+) of different durations and looked for differences overall in hospital survival. Additionally, corresponding treatments and therapeutic modalities, as well as laboratory results, were analyzed. We included 117 patients. Of those, 97 (82.9%) received a VV-ECMO treatment longer than two weeks. We did not find a significant association between ECMO duration (p = 0.15) and increased mortality though a significant correlation between the patients’ age and their probability of survival (p = 0.02). Notably, we found significantly lower interleukin-6 levels with an increase in therapy duration (p < 0.01). Our findings show no association between the duration of ECMO therapy and mortality. Thus, the treatment duration alone may not be used for making assumptions about the prospect of survival. However, attention is also increasingly focused on long-term outcomes, such as post-intensive care syndrome with severe impairments. MDPI 2023-03-25 /pmc/articles/PMC10094941/ /pubmed/37048583 http://dx.doi.org/10.3390/jcm12072499 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Flinspach, Armin N. Raimann, Florian J. Bauer, Frederike Zacharowski, Kai Ippolito, Angelo Booke, Hendrik Therapy and Outcome of Prolonged Veno-Venous ECMO Therapy of Critically Ill ARDS Patients |
title | Therapy and Outcome of Prolonged Veno-Venous ECMO Therapy of Critically Ill ARDS Patients |
title_full | Therapy and Outcome of Prolonged Veno-Venous ECMO Therapy of Critically Ill ARDS Patients |
title_fullStr | Therapy and Outcome of Prolonged Veno-Venous ECMO Therapy of Critically Ill ARDS Patients |
title_full_unstemmed | Therapy and Outcome of Prolonged Veno-Venous ECMO Therapy of Critically Ill ARDS Patients |
title_short | Therapy and Outcome of Prolonged Veno-Venous ECMO Therapy of Critically Ill ARDS Patients |
title_sort | therapy and outcome of prolonged veno-venous ecmo therapy of critically ill ards patients |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10094941/ https://www.ncbi.nlm.nih.gov/pubmed/37048583 http://dx.doi.org/10.3390/jcm12072499 |
work_keys_str_mv | AT flinspacharminn therapyandoutcomeofprolongedvenovenousecmotherapyofcriticallyillardspatients AT raimannflorianj therapyandoutcomeofprolongedvenovenousecmotherapyofcriticallyillardspatients AT bauerfrederike therapyandoutcomeofprolongedvenovenousecmotherapyofcriticallyillardspatients AT zacharowskikai therapyandoutcomeofprolongedvenovenousecmotherapyofcriticallyillardspatients AT ippolitoangelo therapyandoutcomeofprolongedvenovenousecmotherapyofcriticallyillardspatients AT bookehendrik therapyandoutcomeofprolongedvenovenousecmotherapyofcriticallyillardspatients |